Spain· ES:53311
SOBREPIN 8 MG/ML JARABE
A sobrerol product containing sobrerol, registered in Spain by Meiji Pharma Spain S.A..
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- sobrerol
- Manufacturer
- Meiji Pharma Spain S.A.
- Country
- Spain (ES)
- ATC code
- R05CB07
- ATC class
- Sobrerol
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under R05CB07
Sobrerol, as other registers publish it.
- SpainSOBREPIN 100 MG CÁPSULAS DURASMeiji Pharma Spain S.A.
- SpainSOBREPIN infantil 100 mg supositoriosMeiji Pharma Spain S.A.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Italy · Mucodox, Relogen
- Malta · Sopulmin, Sopulmin Paediatric
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e954698d-95ac-4d4a-8ecb-77f496df6c75 GET /v1/drugs/e954698d-95ac-4d4a-8ecb-77f496df6c75?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Sin Receta",
"estado": "{\"aut\":205020000000,\"rev\":1673275851000}",
"nregistro": "53311",
"substance": "sobrerol"
}See everything about sobrerol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.